CHIVAX
Live / Applied — Statement of use — non-final action mailed (as of 10 Sept 2026)
What this means for you
Not registered yet, but its 11 Feb 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97262974
- Mark type
- Stylized text
- Filed
- 11 Feb 2022
- Published for opposition
- 02 May 2023
- Attorney of record
- Kevin M. Bovard
Goods and services
- Class 042 — Scientific and technological services: Biomedical research services; research and development of vaccines and medicines; research, development, engineering and testing services in the fields of immuno pharmaceuticals and vaccines; scientific research; scientific research in the field of vaccines; clinical and pre-clinical development services in the nature of scientific research and conducting clinical trials for others in the fields of infectious diseases and cancers
Owner
- Virion Therapeutics, LLC, Newark, DE, US
- Virion Therapeutics, LLC, Newark, DE, US
Prosecution history
- 10 Sept 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Sept 2026 — NON-FINAL ACTION E-MAILED
- 10 Sept 2026 — SU - NON-FINAL ACTION - WRITTEN
- 25 Aug 2026 — ASSIGNED TO EXAMINER
- 11 Jul 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 26 Jun 2026 — USE AMENDMENT FILED
- 26 Jun 2026 — TEAS STATEMENT OF USE RECEIVED
- 10 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Dec 2025 — SOU EXTENSION 5 GRANTED
- 25 Nov 2025 — SOU EXTENSION 5 FILED
- 26 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Jun 2025 — SOU EXTENSION 4 GRANTED
- 06 Jun 2025 — SOU EXTENSION 4 FILED
- 06 Jun 2025 — SOU TEAS EXTENSION RECEIVED